Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

AUPH

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.91B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Aurinia Pharmaceuticals IncAurinia Pharmaceuticals Inc6.6-53%7.50.1
$7.01

Current Fair Value

53.1% downside

Overvalued by 53.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.91 Billion
Enterprise Value$1.95 Billion
Dividend Yield$- (-)
Earnings per Share$2.14
Beta1.42
Outstanding Shares132,375,000

Return

Return on Equity52.54%ROE
Return on Assets41.19%
Return on Invested Capital20.94%

Valuation & Multiples

P/E Ratio6.64P/E Ratio
PEG14.08PEG
Price to Sales7.47Price to Sales
Price to Book Ratio3.73Price to Book Ratio
Enterprise Value to Revenue6.52
Enterprise Value to EBIT14.58
Enterprise Value to Net Income6
Total Debt to Enterprise0.04
Debt to Equity0.13Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 4, 2026
EPS Estimate
$0.24
Average shareholder expectation
Revenue Estimate
$80.45 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$0.24
Average shareholder expectation
Revenue Estimate
$82.86 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 80.32%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %1.21%▼ 53.79%
Total Invested$27.08M▼ 97.53%
Investors Holding64▼ 211.00%

ESG Score

No data

About Aurinia Pharmaceuticals Inc

CEO: Peter Greenleaf